Search results
Jeremy Levin, D.Phil, MB BChir, is chairman and chief executive officer of Ovid Therapeutics Inc. (NASDAQ: OVID), a public company developing novel medicines to treat epilepsies and seizure-related disorders. Dr. Levin is concurrently the chairman of Opthea (NASDAQ: OPT).
- Our Story
Sitting across from him was Dr. Jeremy Levin, a physician,...
- Ovid Therapeutics Inc.
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO)...
- Our Story
12 wrz 2024 · NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the promotion of Meg Alexander to President and Chief Operating Officer (COO). Alexander will work in collaboration with Ovid ...
Sitting across from him was Dr. Jeremy Levin, a physician, academic and executive, who had just left his role as the global CEO of Teva Pharmaceuticals, the largest generic medicines company in the world. At the time, Levin was expected to take a role at another large pharmaceutical company.
Last week, Ovid’s Chief Executive Officer, Dr. Jeremy M. Levin, and President & Chief Operating Officer, Meg Alexander, participated in a Q&A session at Cantor Fitzgerald’s 2024 Global ...
28 cze 2023 · Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned retirement of Dr. Claude Nicaise. Meg Alexander promoted to Chief Strategy Officer.
24 lis 2023 · On 16 November 2023, Jeremy Levin, CEO and chairman of Ovid Therapeutics, Inc., received the Lifetime Achievement Award at the 19th Annual Scrip Awards in London.
12 wrz 2024 · US neurological diseases specialist Ovid Therapeutics (Nasdaq: OVID) has announced the promotion of Meg Alexander to president and chief operating officer (COO). Ms Alexander will work in collaboration with Ovid’s leadership team to advance Ovid’s development pipeline of potential disease-halting neurotherapeutics and define and execute its ...
